Yisaipu® Provide AS Patients With an Economical Therapeutic Option While Original Biologicals are More Advantageous in the COVID-19 Epidemic Situation

• Main Authors: Hongjuan Lu (Author), Yuanqiong Wang (Author), Xiuwen Wang (Author), Xin Wu (Author), Ling Zhou (Author), Li Lin (Author), Rong Sheng (Author), Haoran Tian (Author), Ting Li (Author), Huji Xu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objectives: Anti-tumor necrosis factor (TNF) agents have been regarded as the most effective treatment for ankylosing spondylitis (AS) so far. However, economic factors limited the prescription of original biologicals in China. Yisaipu® is a biosimilar for etanercept as pre fill syringes (PFS), whic...